Celltrion Healthcare Co., Ltd.
091990
주식 순위
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
주가
$57.75
마지막 동기화: 2024-01-11
시가총액
$9.42B
변동 (1일)
-0.25%
변동 (1년)
0.00%
국가
KR
거래 Celltrion Healthcare Co., Ltd. (091990)
카테고리
Healthcare
Celltrion Healthcare Co., Ltd. (091990)의 수익
2026 기준 수익 TTM: 0
Celltrion Healthcare Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Celltrion Healthcare Co., Ltd.의 수익 기록 (2014 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2022 | $181.92M | 9.09% |
| 2021 | $166.76M | -42.47% |
| 2020 | $289.85M | 344.13% |
| 2019 | $65.26M | 197.71% |
| 2018 | $21.92M | -89.23% |
| 2017 | $203.63M | 49.87% |
| 2016 | $135.87M | 58.71% |
| 2015 | $85.60M | 781.80% |
| 2014 | $9.71M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
